CLOs on the Move

Notal Vision

www.foreseehome.com

 
Notal Vision was founded in 2000 by ophthalmologists and medical device professionals determined to reduce vision loss associated with age-related macular degeration (AMD). With leading experts in the field, this team of medical professionals and scientists developed a new, patented technology for monitoring AMD. This new technology, Preferential Hyperacuity Perimetry, is now providing eye care professionals around the world with valuable clinical data for monitoring patients with AMD.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

NMS Labs

NMS Labs is an international forensic and clinical reference laboratory that is unsurpassed in its scope of toxicology tests, accuracy of results, scientific expertise, and innovation.   The state-of-the-art headquarters includes clinical, forensic and research facilities, a dedicated and secure crime laboratory, and is staffed by more than 200 highly trained professionals.   NMS Labs is passionate about promoting public health and safety.

Health Medical Imaging

Health Medical Imaging is a Oak Lawn, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Peoria Tazewell Pathology Group

Peoria Tazewell Pathology Group is a Peoria, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce is developing two clinical-stage programs as well as advancing and building out its broad and wholly-owned discovery pipeline of immuno-oncology targets, including those expressed on T-regulatory cells, macrophages and stromal cells. Jounce`s lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS and is currently being assessed in a Phase 2 clinical trial. JTX-4014 is a PD-1 inhibitor intended for use in combination with future pipeline products, and Jounce has completed enrollment in the JTX-4014 Phase 1 clinical trial. In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene. For more information, please visit www.jouncetx.com. We have many career opportunities at Jounce and are looking for exceptional individuals who share our passion and perseverance for developing highly durable cancer immunotherapies that can dramatically impact and improve patients` lives.

Alberta Cancer Board

Alberta Cancer Board is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.